ARS Pharmaceuticals, Inc. (SPRY)

ARS Pharmaceuticals Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Year	Current	2023	2022	2021	2020	2019
Market Capitalization	839	526	308	234	1,321	-
Market Cap Growth	60.48%	71.03%	31.66%	-82.32%	-	-
Enterprise Value	616	298	34	183	939	5
PE Ratio	-	-9.68	-8.87	-11.54	-40.11	-
PS Ratio	83911.33	17535.50	233.72	42.43	-	-
PB Ratio	3.75	2.28	1.13	-7.47	3.45	-
P/FCF Ratio	-18.40	-8.85	-7.64	-13.26	-41.15	-
P/OCF Ratio	-18.42	-8.88	-7.67	-13.30	-42.36	-
EV/Sales Ratio	61569.83	9932.63	25.59	33.16	-	-
EV/EBITDA Ratio	-15.37	-5.49	-0.97	-9.12	-30.08	-0.23
EV/EBIT Ratio	-15.35	-5.48	-0.97	-9.02	-28.51	-0.21
EV/FCF Ratio	-14.23	-5.01	-0.84	-10.36	-29.23	-0.27
Debt / Equity Ratio	0.00	0.00	0.00	-0.29	0.01	-0.27
Debt / EBITDA Ratio	0.00	-0.01	-0.01	-0.45	-0.13	-0.69
Debt / FCF Ratio	0.00	0.00	-0.01	-0.51	-0.13	-0.82
Quick Ratio	60.20	95.51	50.40	7.34	40.30	0.59
Current Ratio	60.90	96.92	51.01	7.42	40.69	0.59
Asset Turnover	0	0	0.01	0.02	0	0
Interest Coverage	-	-	-	-	-1135.10	-
Return on Equity (ROE)	-21.10%	-22.20%	-12.50%	-7.90%	-20.30%	51.10%
Return on Assets (ROA)	-20.50%	-21.50%	-12.00%	-7.00%	-16.10%	-111.00%
Return on Capital (ROIC)	-27.67%	-29.23%	-12.99%	87.49%	-8.51%	55.77%
Earnings Yield	-5.92%	-10.33%	-11.28%	-8.67%	-2.49%	-
FCF Yield	-6.39%	-11.30%	-13.09%	-7.54%	-2.43%	-
Buyback Yield / Dilution	-2.40%	-138.30%	-38.39%	-893.01%	-339.94%	-9.45%
Total Shareholder Return	-2.40%	-138.30%	-38.39%	-893.01%	-339.94%	-9.45%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).